Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297152 | 0.97 | POLB (0.35) | POLBPARK7MEN1CYP1A2MAPK1 | |
| SCHEMBL2148315 | 0.86 | POLB (0.32) | POLBPARK7CHRM5 | |
| SCHEMBL29778248 | 0.86 | POLB (0.32) | POLBPARK7CHRM5 | |
| SCHEMBL2292667 | 0.84 | POLB (0.32) | POLBPARK7CHRM5 | |
| SCHEMBL29778203 | 0.81 | KDM4E (0.36) | POLBPARK7MEN1CYP1A2MAPK1 | |
| SCHEMBL2147985 | 0.78 | PFKFB3 (0.32) | POLBPARK7MAPTKDM4ETDP1 | |
| SCHEMBL30478019 | 0.76 | MEN1 (0.36) | POLBPARK7MEN1CYP1A2MAPK1 | |
| SCHEMBL30807540 | 0.76 | KMT2A (0.36) | POLBPARK7MEN1CYP1A2MAPK1 | |
| SCHEMBL14694226 | 0.73 | POLB (0.32) | POLBPARK7 | |
| SCHEMBL29778265 | 0.73 | POLB (0.32) | POLBPARK7MEN1CYP1A2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4039280-A1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | Seagen Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| EP-2558127-B1 | TARGETED PYRROLOBENZODIAZEPINE CONJUGATES | SEAGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190336614-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2019-11-07 | — | — | US | disclosed |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9624227-B2 | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | MEDIMMUNE LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2789622-B1 | Pyrrolobenzodiazepines used to treat proliferative diseases | MEDIMMUNE LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SEAGEN INC. | 2016-05-12 | — | — | US | disclosed |
| US-9242013-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-8940733-B2 | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | SPIROGEN SARL (CH) | 2015-01-27 | — | — | US | disclosed |
| EP-2789622-A1 | Pyrrolobenzodiazepines used to treat proliferative diseases | Spirogen Sàrl (CH) | 2014-10-15 | — | — | EP | disclosed |
| US-20140142090-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN SARL (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8697688-B2 | Pyrrolobenzodiazepines used to treat proliferative diseases | SEATTLE GENETICS INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-8592576-B2 | Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases | SPIROGEN SARL (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130059800-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | SEATTLE GENETICS INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN DEVELOPMENTS SÀRL (CH) | 2013-01-31 | — | — | US | disclosed |
| US-20110201803-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110196148-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | SPIROGEN LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20110162227-A1 | PYRROLOBENZODIAZEPINES | SPIROGEN LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129013-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | POLB 2322/4885PARK7 693/4885MEN1 4353/4885 |
| US-10561739-B2 | Targeted pyrrolobenzodiazapine conjugates | QDPR, SBDS, DNPEP | POLB 2322/4885PARK7 693/4885MEN1 4353/4885 |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | POLB 2322/4885PARK7 693/4885MEN1 4353/4885 |
| US-20110162227-A1 | PYRROLOBENZODIAZEPINES | GRIN2C, ZKSCAN2, ZRANB2 | POLB 715/4885PARK7 350/4885MEN1 1073/4885 |
| US-20110196148-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | CCND2, CCNH, CCND1 | POLB 280/4885PARK7 393/4885MEN1 1437/4885 |
| US-20130059800-A1 | PYRROLOBENZODIAZEPINES USED TO TREAT PROLIFERATIVE DISEASES | CCNB2, CCNB3, CCNB1 | POLB 453/4885PARK7 1140/4885MEN1 408/4885 |
| US-20190336614-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | POLB 2322/4885PARK7 693/4885MEN1 4353/4885 |
| US-20110201803-A1 | PYRROLOBENZODIAZEPINES | HCRTR2, HCRTR1, CBR3 | POLB 1637/4885PARK7 524/4885MEN1 3982/4885 |
| US-20140142090-A1 | UNSYMMETRICAL PYRROLOBENZODIAZEPINE-DIMERS FOR TREATMENT OF PROLIFERATIVE DISEASES | PCNA, CCNB2, CDK4 | POLB 120/4885PARK7 944/4885MEN1 1358/4885 |
| US-20130028919-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | POLB 2322/4885PARK7 693/4885MEN1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.